Coronavirus (COVID-19) ACEi/ARB Investigation

NCT04330300 — Phase 4, Suspended, 2414 participants, National University of Ireland, Galway, Ireland

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial

Registry	NCT04330300, acronym CORONACION
Status	Suspended - Challenges with funding and very low incidence of COVID-19 at Irish study site
Phase	Phase 4
Study type	Interventional; randomized, parallel, masking: none, prevention
Enrollment	2414 (Estimated)
Sponsor	National University of Ireland, Galway, Ireland (Other)
Conditions	Hypertension, COVID-19
Interventions	Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor, Angiotensin receptor blocker (Drug)
Dates	start 2020-04-30, primary completion 2021-07-31 (estimated), completion 2021-12-01 (estimated), first posted 2020-04-01, last updated 2020-06-30
Locations	1 site in Ireland

-Summary

Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require the angiotensin-converting enzyme 2 (ACE-2) receptor for uptake into the human body, there have been questions about whether medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications. One such group of medications are anti-hypertensives that block the renin-angiotensin system, including both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB). Both ACEi and ARB are widely used for the treatment of hypertension. Early reports from China and Italy suggest that many of those who die from COVID-19 have a coexisting history of hypertension. Consequently, there have been questions raised as to whether these 2 types of blood pressure medication might increase the risk of death among patients with COVID-19. However, it is well known that the prevalence of hypertension increases linearly with age. Therefore, it is possible that the high prevalence of hypertension and ACEi/ARB use among persons who die from COVID-19 is simply confounded by age (older people are at risk of both a history of hypertension and dying from COVID-19). Whether these commonly prescribed blood pressure medications increase the risk of COVID-19 or not remains unanswered. Statements from professional cardiology societies on both sides of the Atlantic have called for urgent research into this question. Our study aims to randomize patients with primary (essential) hypertension who are already taking ACEi/ARB to either switch to an alternative BP medication or continue with the ACEi/ARB that they have already been prescribed. Adults with compelling indications for ACEi/ARB will not be enrolled.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Alternative anti-hypertensive medication	Experimental	Drug: Thiazide or Thiazide-like diuretics; Drug: Calcium Channel Blockers	Switch to an alternative BP medication (specifically a Calcium channel blocker \[CCB\] or Thiazide/Thiazide-like diuretic at an equipotent blood pressure lowering dose). The choice of either CCB or Thiazide/Thiazide-like anti-hypertensive provided as alternative therapy will be at the discretion of the patient's treating physician.
Continue ACEi/ARB antihypertensive	Active comparator	Drug: ACE inhibitor; Drug: Angiotensin receptor blocker	Continue with either the ACEi (Angiotensin Converting Enzyme Inhibitor) or the Angiotensin Receptor Blocker (ARB) that had already been prescribed for the treatment of hypertension.

Thiazide or Thiazide-like diuretics (Drug), also known as Hydrochlorothiazide, metolazone, chlorthalidone, chlorothiazide, bendroflumethiazide, indapamide: Anti-hypertensive (Active Arm)
Calcium Channel Blockers (Drug), also known as Amlodipine, diltiazem, felodipine, nicardipine, nifedipine, nimodipine, nitrendipine, verapamil: Anti-hypertensive (Active Arm)
ACE inhibitor (Drug), also known as Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril: Anti-hypertensive (Control Arm)
Angiotensin receptor blocker (Drug), also known as Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan: Anti-hypertensive (Control Arm)

+Outcome measures

Primary outcomes

Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV) [12 months]: Time from randomization to the first occurrence of any of the clinical events above

Secondary outcomes

Number of Covid-19 positive participants who die [12 months]: Time from randomization to the first occurrence of above
Number of Covid-19 positive participants who require intubation in intensive care unit (ICU) [12 months]: Time from randomization to the first occurrence of above
Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV) [12 months]: Time from randomization to the first occurrence of above
Number of SARS-CoV-2 positive participants [12 months]: Time from randomization to the first occurrence of above
Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization [12 months]
24 hour mean systolic BP (mmHg) on ambulatory BP monitoring [12 months]: Performed in a random sub-sample of the cohort (both study arms)
All-cause mortality [12 months]: Time from randomization to the first occurrence of above

+Eligibility

Sex: All, ages: 60 Years to any

Inclusion Criteria:

* Men and non-pregnant women aged 60 or over
* Known diagnosis of hypertension
* Current use of ACEi or ARB for the treatment of hypertension
* COVID-19 naïve (i.e. not known to be infected)
* English speaker

Exclusion Criteria:

* Known diabetic nephropathy
* Known heart failure with reduced ejection fraction
* Resistant hypertension (defined as blood pressure that remains above goal despite concurrent use of three anti-hypertensive agents of different classes, one of which should be a diuretic, or as blood pressure that is controlled with four or more medications)
* Contraindications or allergies to CCB or Thiazide
* Unconscious patients
* Current psychiatric in-patients
* Patients in an emergency medical setting
* Inability to consent

+Locations (1)

Facility	City	Country	Status
University Hospital Galway	Galway	Ireland

+Investigators

John William McEvoy, MBBCh MHS, Principal investigator, National University of Ireland, Galway, Ireland